A team at Illumina Inc. (NASDAQ:ILMN) has developed an AI algorithm that will help identify pathogenic mutations from genome sequencing analyses by including non-human primate data in the training data set, and the approach could be used to identify new targets for personalized therapies.
The deep neural learning network, named PrimateAI, was
